C. Poile

发表

Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial.

C. Richards, D. Fennell, C. Brookes, 2022, The Lancet. Oncology.

Active symptom control with or without oral vinorelbine in patients with relapsed malignant pleural mesothelioma (VIM): A randomised, phase 2 trial

C. Richards, D. Fennell, J. Lester, 2022, EClinicalMedicine.

BAP1 loss induces mitotic defects in mesothelioma cells through BRCA1-dependent and independent mechanisms

D. Fennell, A. Fry, A. Nakas, 2022, Oncogene.

The response of isolated ventricular cardiomyocytes to acute changes in metabolic substrates

C. Poile, C. Poile, 2016 .

Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment

C. Swanton, F. Dudbridge, G. Wilson, 2021, Nature Communications.

Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial

C. Richards, D. Fennell, P. Szlosarek, 2021, The Lancet. Oncology.

Gene fusions during the early evolution of mesothelioma correlate with impaired DNA repair and Hippo pathways

M. Zhang, D. Fennell, A. Nakas, 2023, medRxiv.

Author Correction: Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment

M. Zhang, C. Swanton, F. Dudbridge, 2021, Nature Communications.

A randomized phase II trial of oral vinorelbine as second-line therapy for patients with malignant pleural mesothelioma.

C. Richards, D. Fennell, M. Nicolson, 2021 .

PS01.11 Nivolumab Versus Placebo in Relapsed Malignant Mesothelioma: The CONFIRM Phase 3 Trial

C. Richards, D. Fennell, P. Szlosarek, 2021 .